CellSource Co (TSE:4880) Other Current Liabilities: 円345 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4880 CellSource Co Ltd TSE:4880
69 GF Score
Price 円314.00
GF Value 円780.12
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is CellSource Co Other Current Liabilities?

CellSource Co TSE:4880 -3.09% 69 Other Current Liabilities is 円345 Mil as of Apr. 2026. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円780.12 (Significantly Undervalued). The stock has 6 warning signs investors should review.

CellSource Co's other current liabilities for the quarter that ended in Apr. 2026 was 円345 Mil.

CellSource Co's quarterly other current liabilities declined from Apr. 2025 (円339 Mil) to Oct. 2025 (円261 Mil) but then increased from Oct. 2025 (円261 Mil) to Apr. 2026 (円345 Mil).

CellSource Co's annual other current liabilities increased from Oct. 2023 (円191 Mil) to Oct. 2024 (円223 Mil) and increased from Oct. 2024 (円223 Mil) to Oct. 2025 (円261 Mil).

CellSource Co Other Current Liabilities Related Terms

CellSource Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for CellSource Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellSource Co Other Current Liabilities Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only 89.00 88.41 190.91 222.59 261.01

CellSource Co Semi-Annual Data
Oct17 Oct18 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25 Apr26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 308.58 222.59 338.94 261.01 344.99
TSE:4880
69GF Score
CellSource Co Ltd TSE:4880
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellSource Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円345 Mil mean?
CellSource Co (TSE:4880) has a Other Current Liabilities of 円345 Mil as of Apr. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CellSource Co.
Is CellSource Co's Other Current Liabilities too high?
CellSource Co's current Other Current Liabilities is 円345 Mil. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Other Current Liabilities compare to VRTX and REGN?
CellSource Co's Other Current Liabilities of 円345 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CellSource Co. CellSource Co's current Other Current Liabilities is 円345 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円780.12, compared to a current price of 円314.00 — trading 59.7% below its estimated fair value. The current Other Current Liabilities is 円345 Mil. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Other Current Liabilities is 円345 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellSource Co (TSE:4880) Overvalued in 2026?

Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued. The current stock price of 円314.00 is trading 59.7% below its estimated GF Value™ of 円780.12. GuruFocus considers CellSource Co to be Significantly Undervalued.

Key valuation signals for TSE:4880:

  • Other Current Liabilities: 円345 Mil
  • GF Value™: 円780.12 vs. price of 円314.00 (59.7% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellSource Co Business Description

Address Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score

Get the complete analysis for TSE:4880

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円314.00
Price
円780.12
GF Value